HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Hydrocortisone acetate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, vasodilation, and immune cell activity. Pramoxine hydrochloride is a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, inhibiting nerve impulse conduction and providing topical anesthesia.
| Metabolism | Hydrocortisone acetate is primarily metabolized in the liver via reduction and conjugation. Pramoxine hydrochloride is metabolized hepatically via unknown pathways. |
| Excretion | Hydrocortisone acetate: primarily renal (about 90% as metabolites, less than 1% unchanged); pramoxine HCl: negligible systemic absorption, eliminated primarily via fecal excretion. |
| Half-life | Hydrocortisone acetate: 1.5–2 hours (plasma), clinically adrenocortical suppression lasts 24–48 hours; pramoxine: not applicable due to minimal absorption. |
| Protein binding | Hydrocortisone acetate: about 90–95% bound to corticosteroid-binding globulin (CBG) and albumin; pramoxine: negligible systemic binding. |
| Volume of Distribution | Hydrocortisone acetate: 0.3 L/kg (approximates total body water); pramoxine: not determined due to minimal absorption. |
| Bioavailability | Hydrocortisone acetate: topical absorption <1% (intact skin); pramoxine: negligible systemic bioavailability topically. |
| Onset of Action | Topical: hydrocortisone acetate 1%: relief within 1–24 hours; pramoxine HCl 1%: anesthetic effect within 3–5 minutes. |
| Duration of Action | Hydrocortisone acetate: anti-inflammatory effect lasts 12–24 hours after single application; pramoxine HCl: anesthesia lasts 2–4 hours. |
Apply a thin film to affected area three to four times daily. Topical only.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dosage adjustment necessary for topical use. |
| Liver impairment | No dosage adjustment necessary for topical use. |
| Pediatric use | Apply sparingly to affected area(s) three to four times daily. Use smallest amount for shortest duration necessary. |
| Geriatric use | Use with caution due to potential increased absorption from thinner skin; apply sparingly and avoid prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Breastfeeding | Topical application to small areas is likely compatible with breastfeeding. Avoid application to the nipple or areola to prevent direct infant ingestion. Systemic absorption is minimal, and the M/P ratio is unknown but expected to be low. Use caution with prolonged application to large areas or broken skin. |
| Teratogenic Risk |
■ FDA Black Box Warning
None.
| Common Effects | adrenal insufficiency |
| Serious Effects |
["Hypersensitivity to any component of the product","Vaccinia, varicella, or other viral skin infections","Fungal or bacterial skin infections without concurrent antimicrobial therapy","Tuberculous skin lesions"]
| Precautions | ["Avoid use in the presence of fungal, viral, or bacterial skin infections without appropriate antimicrobial therapy","May cause systemic absorption with prolonged use, especially on large areas, under occlusion, or in pediatric patients","Do not use on deep wounds, puncture wounds, or severe burns","May cause local irritation, allergic contact dermatitis, or secondary infection"] |
| Food/Dietary | No significant food interactions known. Avoid alcohol if it worsens itching or irritation. |
Loading safety data…
| First trimester: Topical corticosteroids are generally considered low risk; however, systemic absorption may occur with prolonged use on large areas or occluded skin. Pramoxine is a local anesthetic with minimal systemic absorption. Available data do not suggest a significant increase in congenital anomalies. Second and third trimesters: No specific fetal risks identified. Avoid prolonged use on large areas or damaged skin to minimize systemic absorption. |
| Fetal Monitoring | No specific maternal or fetal monitoring required for topical use. Monitor for signs of local adverse effects (e.g., skin atrophy, hypersensitivity). In cases of prolonged use on large areas, assess for systemic corticosteroid effects (e.g., adrenal suppression). |
| Fertility Effects | No known effects on fertility. Topical corticosteroids and pramoxine are not associated with reproductive toxicity when used as directed. |
| Clinical Pearls | Combines anti-inflammatory corticosteroid with topical anesthetic for symptomatic relief of pruritus and inflammation. Apply thin layer to affected area 3–4 times daily. Avoid use on infected skin, eyes, or mucous membranes. Discontinue if irritation or sensitization occurs. Prolonged use may lead to local skin atrophy or systemic absorption. Use with caution in pediatric patients due to increased absorption. |
| Patient Advice | For external use only. Do not apply to eyes, mouth, or vagina. · Wash hands before and after application unless treating hands. · Apply a thin layer; do not bandage tightly or cover with occlusive dressings unless directed. · Avoid using on broken or infected skin without medical advice. · Notify your doctor if condition worsens or does not improve after 2 weeks. · Do not use longer than prescribed to avoid skin thinning or systemic effects. |